Founded in 2019, Logos Capital focuses on biotechnology companies involved in new technologies and therapeutic approaches in molecular biology, bioinformatics, and genetic engineering. They combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. With expertise across medical, scientific, and statistical disciplines, Logos Capital expands diligence in identifying compelling investment ideas and achieving uncorrelated-market returns. They use scientific diligence and statistical modeling of clinical trials to gain high conviction in each position.